<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00652522</url>
  </required_header>
  <id_info>
    <org_study_id>AF06003AF</org_study_id>
    <nct_id>NCT00652522</nct_id>
  </id_info>
  <brief_title>Atrial Fibrillation Management in Congestive Heart Failure With Ablation</brief_title>
  <acronym>AMICA</acronym>
  <official_title>Atrial Fibrillation Management in Congestive Heart Failure With Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is the purpose of the study to show the benefit of the endocardial catheter ablation by
      pulmonary vein isolation in patients with persistent or longstanding persistent atrial
      fibrillation, low LVEF and requiring ICD or CRT-D therapy compared to the best medical
      treatment with antiarrhythmic drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation is the most common sustained cardiac arrhythmia affecting 5% of people
      older than 65 years. It is associated with a 5 times increase of the risk of stroke in
      patients who are not receiving anticoagulant therapy and a doubling of the rate of death in
      all patients.

      Congestive heart failure (CHF) and atrial fibrillation (AF) often co-exist, where one
      condition is promoting the development of the other and worsens its condition.

      It is the purpose of the study to show the benefit of the endocardial catheter ablation by
      pulmonary vein isolation in patients with persistent (for a minimum of 1 week to a maximum of
      1 year duration) or longstanding persistent (for a minimum of 1 year to a maximum of 4 years)
      atrial fibrillation, low LVEF (&lt;=35%) and requiring ICD or CRT-D therapy compared to the best
      medical treatment with antiarrhythmic drugs.

      Patients meeting the inclusion and exclusion criteria will be randomized in a 1:1 fashion in
      an unblinded, parallel arm treatment format to either drug therapy (directed at rate or
      rhythm control) or catheter ablation.

      All therapies will be established and optimized in a 3 month treatment initiation phase
      (Blanking Period) starting with randomization. For all morbidity and mortality end-points,
      intention-to-treat analysis will begin at randomization. Efficacy with respect to AF
      treatment will be established for long-term follow up beginning after 3-month initiation
      phase.

      Improvement of LVEF within 12 month is the primary endpoint of this study. The transthoracic
      echocardiographic (TTE) assessment at enrollment, discharge and 12 months follow-up follows a
      standardized protocol. The assessments are analyzed, calculated and expressed by an
      independent Core Lab.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2008</start_date>
  <completion_date type="Actual">July 13, 2017</completion_date>
  <primary_completion_date type="Actual">July 13, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular ejection fraction (LVEF) by transthoracic echocardiography (TTE)</measure>
    <time_frame>12months</time_frame>
    <description>evaluated by Core Lab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence of atrial tachyarrhythmia</measure>
    <time_frame>9 months</time_frame>
    <description>diagnosed by daily ECG via ECG-recording card</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise capacity in 6 min walk test</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>assessed by Minnesota Quality of Life Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF burden</measure>
    <time_frame>9 months</time_frame>
    <description>assessed by ICD/CRT-D device memory in SJM devices</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adequate and inadequate ICD interventions</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">202</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <condition>Heart Failure</condition>
  <condition>ICD</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Best Medical Treatment, ICD/CRT implant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AF Ablation, ICD/CRT implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ICD/CRT implant</intervention_name>
    <description>Implantation of a ICD/ CRT device if not yet implanted</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>ICDs/ CRT-Ds: All St. Jude Medical device</other_name>
    <other_name>RA, RV and LV leads: St. Jude Medical CE-marked leads recommended</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>AF ablation</intervention_name>
    <description>Atrial Fibrillation ablation by pulmonary vein isolation</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Catheters: St. Jude Medical CE-marked catheters recommended</other_name>
    <other_name>NavX system for 3D mapping</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Medical Treatment</intervention_name>
    <description>Best medical treatment according to current guidelines for Management of Patients with Atrial Fibrillation and for Management of Chronic Heart Failure.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Conventional rate or rhythm control according valid guidelines</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Having signed and dated Patient Informed Consent

          -  Having an indication for ICD or CRT-D therapy as indicated by current valid guidelines
             or having been implanted with an ICD or CRT-D

          -  Symptomatic atrial fibrillation (persistent AF (for a minimum of 1 week to a maximum
             of 1 year) or longstanding persistent AF (for a minimum of 1 year to a maximum of 4
             years)) irrespective of the duration of paroxysmal AF

          -  Ejection fraction â‰¤ 35% as assessed by transthoracic echocardiography

          -  Left atrial diameter of less than 60 mm in parasternal diameter during transthoracic
             echocardiographic study

          -  ECG documentation of atrial fibrillation (ECG, Holter, event recorders, etc) related
             to symptomatic episodes

          -  Having typical symptoms of heart failure NYHA II - III

          -  Patients &gt; 30 days under optimal medical treatment for heart failure and CRT therapy
             in case of a pre-implanted CRT-D device

          -  Age 18 - 75 years

          -  Willing to participate in randomized trial

          -  Willing and able to participate in 12 months follow-up period

        Exclusion Criteria:

          -  Longstanding persistent (&gt; 4 years history) or paroxysmal atrial fibrillation

          -  Having a previously implanted pacemaker

          -  Having underlying valvular heart disease unless the disease has been corrected

          -  Patients with acute myocardial infarction

          -  Patients who have had previous pulmonary vein isolation procedures

          -  Patients with atrial fibrillation secondary to a reversible cause

          -  Known presence of intracardiac or other thrombi

          -  Pregnant females or those of child bearing potential who have not had a negative
             pregnancy test within 48 hours before treatment

          -  Patients with other medical condition (i.e., cancer, alcoholism, drug abuse) that may
             cause the patient to be non-compliant with the protocol, confound the data
             interpretation or is associated with limited life-expectancy (i.e., less than one
             year)

          -  History of bleeding diathesis or suspected pro-coagulant state

          -  Contraindication to anticoagulation therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl-Heinz Kuck, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asklepios Klinik St. Georg - Hamburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herz- und Gefaesszentrum Bad Bevensen</name>
      <address>
        <city>Bad Bevensen</city>
        <zip>29549</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤ts-Herzzentrum Freiburg - Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff-Klinik gGmbH</name>
      <address>
        <city>Bad Nauheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsmedizin Berlin - CharitÃ© Campus Virchow-Klinikum (CVK)</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤res Herzzentrum Hamburg GmbH / UKE</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Ruprecht-Karls-UniversitÃ¤t Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ingolstadt GmbH</name>
      <address>
        <city>Ingolstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Ludwigshafen am Rhein gGmbH</name>
      <address>
        <city>Ludwigshafen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum GroÃŸhadern der Ludwig-Maximilians-UniversitÃ¤t</name>
      <address>
        <city>MÃ¼nchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum am UniversitÃ¤tsklinikum MÃ¼nster</name>
      <address>
        <city>MÃ¼nster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Adolf-Stift Reinbek</name>
      <address>
        <city>Reinbek</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Clinic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2008</study_first_submitted>
  <study_first_submitted_qc>March 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2008</study_first_posted>
  <last_update_submitted>August 9, 2017</last_update_submitted>
  <last_update_submitted_qc>August 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AF ablation</keyword>
  <keyword>Pulmonary vein isolation(PVI)</keyword>
  <keyword>reduced LV ejection fraction</keyword>
  <keyword>symptomatic atrial fibrillation</keyword>
  <keyword>persistent AF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

